

E-mail: dr\_jackieo@yahoo.com

Phone: 469-271-7829



**Jacqueline G. O'Leary, MD MPH**

03/25/2025

**Work Experience:**

2018-Present **Chief of Hepatology, Dallas VA**  
2017-2018 **Supervisor Hepatologist at the Dallas VA**  
2015-2017 **Medical Director of Research, Baylor Simmons Transplant Institute**  
Baylor University Medical Center  
2015-2016 **Medical Director of Hepatology Research, Texas Digestive Disease Consultants**  
2013-2016 **Medical Director, Baylor Simmons Transplant Institute**  
Baylor University Medical Center  
2012-2017 **Senior Investigator, Liver Transplant Biorepository**  
2008-2017 **Medical Director, Inpatient Liver and Transplant Unit**  
Baylor University Medical Center.  
2006-2017 **Baylor Regional Transplant Institute, Dallas, Texas**  
Hepatologist, Baylor University Medical Center

**Education:**

2011-13 **Southern Methodist University, School of Business**  
Advanced Physician Leadership Program  
2005-06 **Massachusetts General Hospital, Boston, Massachusetts**  
Transplant Hepatology Fellowship Training Program  
2004-06 **Harvard School of Public Health**  
Masters In Public Health, Clinical Effectiveness Tract  
2002-05 **Massachusetts General Hospital, Boston, Massachusetts**  
Gastroenterology Fellowship Training Program  
1999-02 **University of Texas, Southwestern Medical Center, Dallas, Texas**  
Internal Medicine Residency  
1996-99 **University of California, San Francisco, School of Medicine, San Francisco, California**  
MD with Thesis degree.  
1995-99 **University of California, San Francisco, School of Medicine, San Francisco, California**  
M.D.  
1991-95 **Stanford University, Palo Alto, California**  
B.S. with honors and distinction, Biological Sciences

**Awards & Honors:**

2024 **"2024 Top Provider"** All VA North Texas providers vote for the provider they trust the most in each specialty, but only one for the entire medical center is selected each year as the top provider.  
2024 **Best Doctors in Dallas**  
2024 **VHANTX Top Provider** for Hepatology for 2024  
2024 **VHANTX Award from the Director for Excellence in Clinical Care**  
2023 **VHANTX Top Provider** for Hepatology for 2023  
2022 Promotion to **Professor of Medicine, UTSW**  
2020 **Bilhartz UTSW GI Fellowship Teaching Award.**  
2020 **Liver Transplantation – Top Cited Article**  
2019 **VHANTX Top Provider** for Hepatology for 2019  
2018 **I-CARE award of Commitment**, given by Peter O'Rourke, Secretary of the VA  
2018 **I-CARE award of Commitment** for Hepatology, Dallas VA

E-mail: dr\_jackieo@yahoo.com

Phone: 469-271-7829

2017	<b>I-CARE award of Excellence</b> for HCV Treatment, National VA HIT Collaborative
2017	<b>CIA Award</b> , Dallas VA
2017	<b>"Bridging acute or acute-on-chronic liver failure patients to transplant"</b> <b>AASLD Post-graduate course, Washington DC</b>
2017	<b>Fellow in the American Society of Transplantation</b>
2016	<b>Young Investigator Award from International Liver Transplant Society</b>
2015	<b>AJT Top 10 Editors pick for 2015</b>
2015	<b>Co-Chair DDW Post-Graduate Course: Evidence that will Change Your Practice: New advances for common clinical problems</b>
2015	<b>AST Clinical Science Investigator Award</b>
2014	<b>Fellow in the American Gastroenterology Association</b>
2013	<b>Young Investigator Award from International Liver Transplant Society</b>
2013-16	<b>Best Doctors in America</b>
2013	<b>Fellow in the American College of Gastroenterology</b>
2012	<b>Clinical Assistant Professor at Texas A &amp; M Health Science Center</b>
2012	<b>"Curing Chronic Viral Hepatitis C: The new world of antiviral therapy"</b> <b>Presidential Plenary at DDW, San Diego, CA</b>
2012	<b>Young Investigator Award from International Liver Transplant Society</b>
2011-16	<b>US News &amp; World Report Top Doctors</b>
2008-16	<b>Best Doctors in Dallas</b>
2005	<b>AASLD Advanced Hepatology Fellowship travel grant</b>
2005	<b>AASLD Advanced Hepatology Fellowship Award for \$60,000</b>
1997	<b>American Society of Hematology Scholarship Award</b>
1996	<b>Jane Shohl Colburn Research Fellowship</b>
1994	<b>Pfizer Summer Fellowship</b>
1994	<b>Johnson Pharmaceutical Research Travel Award</b>
1993	<b>Undergraduate Research Fellowship</b>
1991	<b>Irvine Company Scholarship</b>

#### **Certification and Licensure:**

2018	MOC Recertification in Liver Transplant Hepatology
2008	Board Certification in Liver Transplant Hepatology
2006	Board Certification in Gastroenterology
2006	State of Texas Physician License L2514
2002	Board Certification in Internal Medicine
1999	USMLE, Step I: 247, USMLE, Step II: 232, USMLE, Step III: 244

#### **Research Experience:**

2005-06	<b>Massachusetts General Hospital GI Unit</b> Mentored clinical research experience with Dr. Raymond Chung. Developed the idea, wrote, conducted, and published a clinical trial to treat HCV. It was unsuccessful therapeutically but successfully completed in 1 year. The results stopped further development of HMG-Co-A reductase inhibition as an adjunct to HCV therapy. <b>O'Leary JG</b> , Chan JL, McMahon CM, Chung RT. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. <i>Hepatology</i> 45:895-898, 2007.
2003-05	<b>Center for Blood Research, Harvard University</b>

E-mail: dr\_jackieo@yahoo.com

Phone: 469-271-7829

Post-doctoral Fellow: Under Ulrich von Andrian MD PhD, I study delayed type hypersensitivity documenting NK cell memory for the first time.

**O'Leary JG**, Goodarzi M, Drayton, DL, von Andrian, UH: T and B cell-independent adaptive immunity mediated by natural killer cells. *Nature Immunology*.7: 507-516,2006.

1996-99 **Cancer Research Institute, UCSF**

Research Assistant during the summer after 1<sup>st</sup> and 2<sup>nd</sup> year medical school and during clinical rotations of 3<sup>rd</sup> year medical school without dedicated time: Under Marc Shuman MD, I identified a new protease and created a novel *in vivo* mouse model for prostate cancer in which angiogenesis and invasion were blocked with a protease inhibitor.

I wrote a thesis only on this for an extra degree that they awarded me in retrospect even though I did not comply with the required year off to complete the project.

1992-94 **Synthetic Organic Chemistry Laboratory, Stanford University**

Research Assistant: Under Paul A. Wender PhD, I synthesized a second-generation photochemically activatable Dynemicin analog, tested its DNA cleaving ability, and designed a DNA binding agent to increase its cleavage specificity. I then optimized its synthesis to improve yield.

Wender PA, Beckham S, **O'Leary JG**: A Second-Generation Photochemically Activatable Dynemicin Analog: A Concise Synthesis and DNA Cleavage Studies. *Synthesis*, Special Issue: 1278-1282, 1994.

**Conference Organization:**

- 2024 Banff Liver Pathology Organizing Committee; Paris France
- 2024-2025 Co-Chair of "Desert Liver Conference", Phoenix, AZ
- 2022 Banff Liver Pathology Organizing Committee; Banff CA
- 2016 Co-Chair Antibody Mediated Rejection in Liver Transplantation Meeting, Dallas, TX March 2016.
- 2016 AST CEOT Planning Committee
- 2015-2016 ILTS Planning Committee
- 2015-2016 ATC Planning Committee
- 2015 Co-Chair DDW Post-Graduate Course: Evidence that will Change Your Practice: New advances for common clinical problems
- 2015 Co-Chair AASLD SIG Transplant Symposium
- 2014-2021 Co-Chair National Liver Conference
- 2013 Co-Chair Antibody Mediated Rejection in Liver Transplantation Meeting, Dallas, TX March 2013.
- 2012 Co-Chair and moderator of the 8<sup>th</sup> annual Hepatology & GI Roundup Dallas, TX, September 2012.
- 2011 Co-Chair and moderator of the 7<sup>th</sup> annual Hepatology & GI Roundup Dallas, TX, September 2011.

**Invited Lectures:**

- 2025 "Preventing Complications in Cirrhosis" Desert Liver Conference, Phoenix, AZ
- 2025 "AASLD HCC Debrief", AASLD-TASL, Istanbul, Turkey
- 2025 "AASLD Portal Hypertension Debrief", AASLD-TASL, Istanbul, Turkey
- 2025 "AASLD Liver Transplant Debrief", AASLD-TASL, Istanbul, Turkey

E-mail: dr\_jackieo@yahoo.com

Phone: 469-271-7829

- 2024 Meet the Expert “Balancing Act of Immunosuppression: Not too much, not too little” AASLD, San Diego, CA
- 2024 “Liver Transplantation Debrief” AASLD, San Diego, CA
- 2024 “Editor’s Cut: PBC, AIH & ESLD” AASLD, San Diego, CA
- 2024 “Banff Liver Sessions Wrap Up”, TTS Virtual / In-person Meeting, Istanbul, Turkey
- 2024 “VA Health Equity Round Table - Liver Cancer” Webinar, National VA Broadcast from Global Liver Institute.
- 2024 “Monitoring Aspects of Chronic AMR and Potential Approaches to Treatment”, Banff Meeting of Allograft Pathology, Paris, France
- 2024 “Liver Sessions Wrap Up”, Banff Meeting of Allograft Pathology, Paris, France
- 2024 “Portal Hypertension”, AASLD Transplant Hepatology Board Review Course Lecture.
- 2024 “AKI in Cirrhosis” Liver Connect Echo, Indian Health Service, Alaska Broadcast
- 2024 “Update in cirrhosis: From HRS to HCC” Desert Liver Conference, Phoenix AZ
- 2023 “All patients with ascites should receive prophylactic antibiotics” Debate at the AASLD Post-Graduate Course, Boston, MA
- 2023 “Septic Shock in ACLF” ACLF SIG program AASLD, Boston, MA
- 2023 “Editor’s Cut: MASH, ALD and ESLD” AASLD, Boston, MA
- 2023 “ACLF” UTSW 7<sup>th</sup> Annual Update on Liver Disease, Dallas, TX
- 2023 “Portal HTN in Cirrhosis – New Perspectives on Old Problems” TSGE, San Antonio TX
- 2023 “Liver AMR: Reality or Myth?” Baylor College of Medicine Transplant Grand Rounds, Houston, TX.
- 2023 “Preventing Complications in Patients with Cirrhosis” Desert Liver Conference, Scottsdale AZ.
- 2022 HIT National VA Broadcast: “ACLF Guidelines”
- 2022 “ACLF Guidelines” VA Hot Topics, AASLD Washington DC
- 2022 “Defining the role of invasive and non-invasive biomarkers in tolerance and AMR” Invited talk at AASLD, Washington DC
- 2022 “ACLF” UTSW 6<sup>th</sup> Annual Update on Liver Disease, Dallas, TX
- 2022 “Decision Making in 2030: How do we put it all together” Invited talk at Banff International Histopathology, Banff, Canada.
- 2022 “Predictors of Survival and Therapies for ACLF”, Invited talk at DDW, San Diego, CA, 2022
- 2022 HIT National VA Broadcast: “AASLD Portal HTN Update”, 2/2/2022.
- 2021 ‘Novel Anticoagulants in liver disease and the risk of DILI’ Invited virtual talk at AASLD 2021.
- 2021 “Meet the Expert: Non-infectious Triggers of ACLF” AASLD, virtual meeting 2021.
- 2021 “Optimizing Inpatient Outcomes” National Liver Conference, San Antonio, TX
- 2021 Moderator of the “Portal Hypertension Panel” National Liver Conference, San Antonio, TX
- 2021 “Optimizing Long-Term Outcomes of Liver Transplant Recipients” Taiwan Surgical Association, Virtual presentation to Taipei Taiwan, 8/21.

E-mail: dr\_jackieo@yahoo.com

Phone: 469-271-7829

- 2021 "We should explore using our current treatment in a more efficient and personalized way." CEOT virtual AST meeting, 2/21.
- 2021 "Optimizing patient transplant care: Clinical implications of tacrolimus levels for liver transplant recipients". Multiorgan Transplant Grand Rounds, London Health Science Center, London, Canada, 2/21.
- 2021 "Optimizing patient transplant care: Clinical implications of tacrolimus levels for liver transplant recipients". Multiorgan Transplant Grand Rounds, University of Toronto, Toronto, Canada 2/21.
- 2020 "Relevance of Preformed and De Novo DSA in Liver Transplantation" ILTS international broadcast webinar, 12/2020.
- 2020 "ACLF: Evolving Concepts" Virtual AASLD Post-Graduate Course, 11/2020.
- 2020 "Management of Preformed DSA and LCM+ Patients" TTS annual meeting, Montreal, Canada.
- 2020 "ACLF" UTSW 5<sup>th</sup> Annual Hepatology Conference
- 2019 "Liver Transplantation for ACLF: The North American Experience" ACLF/APPASL SIG program at AASLD, Boston, MA
- 2019 "Chronic Antibody Mediated Rejection: Detection and Treatment" Liver Transplant and Pediatric SIG program at AASLD, Boston, MA
- 2019 "Abstract and Poster Presentation Best Practices" Early Morning Workshop, AASLD, Boston MA.
- 2019 "Morphologic characterization of Chronic Liver Allograft AMR" Banff Meeting of Histopathology, Pittsburg PA
- 2019 "ACLF" Grand Rounds, UTSW, Dallas, TX
- 2019 "Diagnosis of AMR: What the clinician needs to know." ATC, Boston MA
- 2019 "ACLF" UTSW 4<sup>th</sup> Annual Hepatology Conference
- 2018 "Biomarkers in Liver Disease" National Liver Conference, Austin TX.
- 2018 "AMR in Liver Transplantation" TTS Webinar.
- 2017 "Preventing Readmissions", AASLD Early Morning Workshop, Washington DC
- 2017 STAR international working group to develop consensus guidelines for HLA testing and DSA in solid organ transplant patients.
- 2016 "Chronic AMR" Antibody Mediated Rejection in Liver Transplantation, Dallas, TX 2016.
- 2015 "Niches of Need in Immunosuppression" AASLD Transplant SIG Program, San Francisco, CA, 2015.
- 2015 "DSA in Liver Transplantation" TTS Basic Science Symposium, Lorne Australia 2015.
- 2015 "DSA in Liver Transplantation" Guest of Honor at the 25<sup>th</sup> Anniversary Danish Transplant Society Meeting. Copenhagen, Denmark 10/2015.
- 2015 "DSA Pre-Liver Transplant" Brazilian Society for Transplant, Gramando, Brazil, 10/2015.
- 2015 "DSA Post-Liver Transplant" Brazilian Society for Transplant, Gramando, Brazil, 10/2015.
- 2015 "DSA in Liver Transplant" Brazilian Society for Transplant, Gramando, Brazil, 10/2015.
- 2015 "Chronic Antibody Mediated Rejection: Perspectives & Issues" Banff-CST Scientific Meeting, Vancouver, Canada 2015.
- 2015 "Hepatitis C: Screening and Treatment" Loma Linda Liver Day, Palm Springs, CA 2015.

E-mail: dr\_jackieo@yahoo.com

Phone: 469-271-7829

- 2015 "Acute-on Chronic Liver Failure" National Liver Conference, Dallas TX, 2015.
- 2015 "DSA in Liver Transplantation" Transplant Grand Rounds, Mayo Clinic, Rochester MN, 2015.
- 2015 "DSAs are Important in Influencing Outcomes" Current Controversies in Liver Transplantation, ILTS, Chicago IL, 2015.
- 2015 "DSA: Biomarker or Pathogen?" ILTS Chicago IL, 2015.
- 2015 "DSA in Liver Transplantation" Penn Transplant Interdisciplinary Series at the Penn Transplant Institute, 2015.
- 2015 "Treatment strategies for AKI in cirrhosis" DDW, Washington DC, 2015
- 2015 "Assessing Surgical Risk in Cirrhosis" DDW, Washington DC, 2015
- 2015 "The Lumpy Liver" DDW post-graduate course clinical breakout session, Washington DC, 2015.
- 2015 "Update in Hepatitis C" Grand Rounds at Baylor Carrollton, Carrollton TX 2015
- 2015 "Prevention and Treatment of AMR in Liver Transplantation" Early Morning Workshop, American Transplant Congress, Philadelphia, PA, 2015
- 2015 Humoral Immune Response in Transplantation: Friend or Foe. "The Impact of Alloantibody on the Liver Allograft" Birmingham AL, 2015.
- 2015 Controversies in Transplant Conference "Are Donor Specific Antibodies Relevant in Liver Transplant?" Breckenridge Colorado.
- 2015 Astellas PanEuropean Advancing Transplantation: New questions, New Possibilities: "The graft journey and risk management: DSA", Stockholm Sweden, 2015.
- 2015 American Gastroenterological Association 2015 AGA Clinical Congress: "New Treatments of HCV", Miami, FL 2015.
- 2015 University of Pennsylvania Viral Hepatitis Grand Rounds: "HCV in the Post-Transplant or Decompensated Patient" Philadelphia, PA 2015.
- 2014 Debate – A bridge too far: NAFLD will not exhaust the donor pool. Invited talk at AASLD/ILTS Transplant Course, Boston, MA 2014.
- 2014 "Peritransplant management of HCV infection. "Early morning workshop AASLD, Boston, MA 2014.
- 2014 "Treatment of renal dysfunction in cirrhosis: The role of liver transplant vs. simultaneous liver-kidney transplant. AASLD SIG program Boston MA, 2014.
- 2014 "DSA in Liver Transplantation" German Society for Transplant. Mannheim Germany, 2014.
- 2014 "DSA in Liver Transplantation: Definitions, Diagnosis and Treatment" Invited talk at WTC early morning workshop, San Francisco, CA, 2014.
- 2014 "Infections in Cirrhosis" National Liver Conference, Dallas TX, 2014.
- 2014 "DSA in Liver Transplantation" Invited talk at Texas Transplant Society Annual Meeting, San Antonio, TX 2014
- 2014 "DSA in Liver Transplantation" Invited talk at Immunosuppression in solid organ transplantation meeting, Argentina
- 2014 International Liver Transplant Society: "Liver Eaters", London, England, 2014.
- 2014 Plenary talk "The 2-Hit Hypothesis of Liver AMR" European Clinical Histocompatibility Workshop, Marbella, Spain, 2014.
- 2014 Plenary talk "Many Faces of DSA in Liver Transplantation" US Clinical Histocompatibility Workshop, Tucson Arizona, 2014.

E-mail: dr\_jackieo@yahoo.com

Phone: 469-271-7829

- 2014 Visiting Professor at Northwestern University Feinberg School of Medicine: "Role of Donor-Specific Alloantibodies in Liver Transplantation" Chicago, IL 2014.
- 2014 Visiting Professor at Toronto General Hospital: "Role of Donor-Specific Alloantibodies in Liver Transplantation" Toronto, Canada 2014.
- 2014 AST Timely Topics in Transplant national webinar: "HCV Eradication: Liver Transplantation and Beyond" 2014.
- 2014 DECTA single topic conference: "Implications of donor-specific HLA antibodies in liver transplantation", Madrid, Spain 2014.
- 2014 Terasaki Festschrift: "Antibody Mediated Rejection in Liver Transplantation", Los Angeles, CA 2014.
- 2014 American Gastroenterological Association 2014 AGA Clinical Congress: New Treatments of HCV: How to I make sense of the options", Miami, FL 2014.
- 2013 Baylor Research Institute Focus on Research invited lecture on: "Antibody Mediated Rejection in Liver Transplantation". Dallas, TX, 2013
- 2013 Meet-the-Professor AASLD Luncheon "OLT: Improving Long-term outcomes" Washington, DC, 2013.
- 2013 Current Topics in Histocompatibility and Transplantation: "Antibody Mediated Rejection in Liver Transplantation", Live National Broadcast.
- 2013 Visiting professor University of Pittsburg: "Role of Donor-Specific Antibodies in Liver Transplantation", Pittsburg, PA September 2013
- 2013 Visiting professor University of Cincinnati: "Role of Donor-Specific Antibodies in Liver Transplantation", Cincinnati, OH July 2013
- 2013 International Banff Meeting Invited talk: "Donor-Specific Antibodies in Liver Transplantation-BUMC Experience", Brazil, August 2013.
- 2013 American Transplant Congress Debate: Relevance of Donor Specific Antibodies in Liver Transplantation "Pro: Donor-Specific Antibodies Are Important and Should Be Performed in Liver Transplant Recipients", Seattle, WA May 2013
- 2013 Antibody Mediated Rejection in Liver Transplantation Meeting "Donor Specific Antibodies in Rejection in Liver Transplantation", Dallas, TX March 2013
- 2013 "Newest Evidence to Thwart the Impact of Hepatitis C" CME event by PRIME, March 2013.
- 2013 British Society of Transplantation "HLA Antibodies and Liver Transplantation", Bournemouth, England March 2013
- 2013 Controversies in Transplant Conference "Donor Specific Antibodies-Role in Liver Transplantation", Breckenridge Colorado.
- 2013 AST Timely Topics in Transplant "HCV Treatment Pre- & Post-Liver Transplant with Triple Therapy" February 2013.
- 2012 "HCV treatment with triple therapy in the Liver Transplant Recipient" HCV SIG Symposium AASLD 2012.
- 2012 Moderator of "HCV New Agents: Hard to Treat Patients" AASLD, Boston, MA 2012.
- 2012 Co-Chair and moderator of the 8<sup>th</sup> annual Hepatology & GI Roundup "Difficult to treat HCV Patients" Dallas, TX, September 2012.
- 2012 "Curing Chronic Viral Hepatitis C: The new world of antiviral therapy" Presidential Plenary at DDW, San Diego, CA 2012

E-mail: dr\_jackieo@yahoo.com

Phone: 469-271-7829

- 2012 "Hepatitis C: The new wave of curative therapy" Amarillo Endoscopy Center 1<sup>st</sup> Annual GI Symposium.
- 2012 "Antibody diagnostics in liver and liver-kidney transplantation" Canadian Society of Transplant annual scientific conference, Quebec City, Canada, 2012
- 2011 Moderator of "Epidemiology and Diagnosis of Hepatobiliary Neoplasia" AASLD, San Francisco, CA 2011
- 2011 Hepatology & GI Roundup "To IL28B or not to Be and other conundrums in hepatitis C" Dallas, TX, September 2011.
- 2010 "Treatment of hyponatremia and refractory ascites" Co-Chair and moderator of the 6<sup>th</sup> annual Hepatology & GI Roundup, Dallas, TX, September 2010.
- 2009 "Long-term management of the post-liver transplant patient by the general internist" 5<sup>th</sup> annual Hepatology & GI Roundup, Dallas, TX, April 2009.
- 2008 "Management of Cirrhosis" TSGE annual meeting, Dallas, TX, September 2008.

**Published original articles:**

- 2025 Gallegos-Orozco JF, **O'Leary JG**, Reddy G, Bindra J, Chopra I, Niewoehner J, Huang X. Early Diagnosis of Hepatorenal Syndrome and Timely Treatment with Terlipressin Improve Clinical Outcomes and Healthcare Efficiency. Submitted to *Hepatology Communications*.
- 2025 Bajaj JS, Wong F, Kwo P, Pappas SC, **O'Leary JG**, Jamil K, Cardoza S. Bradycardia and other arrhythmias in patients with hepatorenal syndrome-acute kidney injury following terlipressin treatment: A pooled analysis of three North American Phase III clinical studies. Submitted to *APT*.
- 2025 Shabbir R, Garrido-Trevino L, **O'Leary JG**, Chaudhary A, Maiwall R, Arora V, Tevethia HV, Sarin SK, Hall L, Ogola GO, Patrick S, Kamath PS, Asrani SK. MELD-Lactate and lactate clearance in critically ill cirrhosis patients with sepsis. Submitted to *Hepatology*.
- 2025 Bajaj JS, Tandon P, Thuluvath PJ, Wong F, Kamath PS, Vargas H, Asrani S, **O'Leary JG**, Thacker L, Reddy KR. Lower inpatient mortality and second infections in inpatients with cirrhosis managed between 2021-22 than between 2011-13 in prospective North American cohorts. Submitted to *Clinical Gastroenterology and Hepatology*.
- 2025 Silvey S, Nadeem M, Sterling RK, Markley JD, French E, Patel NR, **O'Leary JG**, Bajaj JS. Secondary SBP Prophylaxis is associated with a higher rate of non-SBP infections in Two US-based National Cirrhosis Cohorts. *Clinical and Translational Gastroenterology, ePub, PMID 40062879*.
- 2025 Silvey S, Patel N, **O'Leary JG**, Bajaj JS. Enhancement of cirrhosis mortality prediction by including hepatic encephalopathy to MELD 3.0 in a National Veteran Cohort. *American Journal of Gastroenterology, ePub, PMID 39836914*.
- 2025 Wong F, Reddy KR, Tandon P, Lai JC, Garcia-Tsao G, **O'Leary JG**, Biggins S, Vargas HE, Thacker L, Bajaj JS. Sex differences in patient-reported outcomes and perception of ascites burden amongst outpatients with decompensated cirrhosis and ascites. *American Journal of Gastroenterology, ePub PMID: 39601412*.
- 2025 Silvey S, Nadeem M, Tsai SY, Sterling RK, Markley JD, French E, Patel NR, **O'Leary JG**, Bajaj JS. High rate of SBP recurrence with secondary



- SBP prophylaxis compared to no prophylaxis in two national cirrhosis cohorts. *American Journal of Gastroenterology*, ePub, PMID 39235290.
- 2025 Butt AA, Yan P, Rahel I, **O'Leary JG**, Shaikh OS, Bedimo R. Hepatitis Delta Coinfection Rates and All-cause mortality among Hepatitis B Infected Veterans in the United States. *Journal of Viral Hepatitis*, 32:e14021, PMID 39382175.
- 2025 Cotter TG, Anouti A, Zhang B, Patel M, Lieber SR, Rich NE, Louissaint J, **O'Leary JG**, Mitchell MC, Singal AG. The current trends of inpatient disparities among alcohol-associated liver disease patients in the United States. *APT*, 61:988-999, 2025, PMID: 39821471.
- 2024 Bajaj JS, **O'Leary JG**, Jakab SS, Fagan A, Sikaroodi M, Gillevet PM. Gut Microbiota Composition can Exclude the Diagnosis of Minimal Hepatic Encephalopathy in Patients with Cirrhosis and Cognitive Complaints. *Gut Microbes* 2024, PMID 39189586.
- 2024 Silvey S, Patel N, Liu J, Tafader A, Nadeem M, Dhaliwal G, **O'Leary JG**, Patton H, Morgan TR, Rogal S, Bajaj JS. A Machine Learning Algorithm Avoids Unnecessary Paracentesis for Exclusion of SBP in Cirrhosis. *Clinical Gastroenterology and Hepatology*, 12:2442-2450; 2024. PMID 38906441.
- 2024 Bellamy COC, **O'Leary JG**, Adeyi O, Baddour N, Batal I, Bucuvalas J, Del Bello A, El Hag M, El-Monayeri M, Farris AB 3rd, Feng S, Fiel MI, Fischer SE, Fung J, Grzyb K, Guimei M, Haga H, Hart J, Jackson AM, Jaeckel E, Khurram NA, Knechtle SJ, Lesniak D, Levitsky J, McCaughan G, McKenzie C, Mescoli C, Miquel R, Minervini MI, Nasser IA, Neil D, O'Neil MF, Pappo O, Randhawa P, Ruiz P, Fueyo AS, Schady D, Schiano T, Sebahg M, Smith M, Stevenson HL, Taner T, Taubert R, Thung S, Trunecka P, Wang HL, Wood-Trageser M, Yilmaz F, Zen Y, Zeevi A, Demetris AJ. Banff 2022 Liver Group Meeting Report: Monitoring Long Term Allograft Health. *American Journal of Transplantation*, 24: 905-17; 2024. PMID: 38461883.
- 2024 Bajaj JS, Silvey S, Rogal S, **O'Leary JG**, Patton H, Morgan TR, Kanagalingam G, Gentili A, Godschalk M, Patel N. Undiagnosed Cirrhosis and Potential Hepatic Encephalopathy in A National Cohort of Veterans with Dementia. *JAMA Open* 2024, PMID: 38294815.
- 2024 Karvellas CJ, Bajaj JS, Kamath PS, Napolitano L, **O'Leary JG**, Sola E, Subramanian R, Wong F, Asrani SK. AASLD Practice Guidance on Acute-on chronic liver failure and the management of critically ill patients with cirrhosis. *Hepatology*, 79: 1463-1502; 2024 PMID: 38461883.
- 2024 Cotter TG, Mitchell MC, Patel M, Lieber SR; Rich NE; Arab JP; Miguel LA, Louissaint J, Patel MS, VanWagner LB, Lee WM, **O'Leary JG**, Singal AG. Racial and Ethnic Disparities in Liver Transplantation for Alcohol-Associated Liver Diseases in the United States. *Transplantation* 108:225-34; 2024; PMID 37340542
- 2023 Badal BD, Silvey S, Dragilev L, **O'Leary JG**, Morgan TR, Cheung R, Patel A, Rogal S, Patton H, Nobbe A, Jakab SS, Liu J, Patel N, Bajaj JS. Primary Prophylaxis for Spontaneous Bacterial Peritonitis is linked to antibiotic resistance in the Veterans Health Administration. *Hepatology* 77: 2030-2040, 2023.
- 2023 Bajaj JS, Tandon P, **O'Leary JG**, Reddy KR, Garcia-Tsao G, Thuluvath P, Lai JC, Subramanian RM, Vargas HE, Wong F, Fagan A, McGeorge S, Thacker LR, Kamath PS. Admission serum metabolites and thyroxine

- predict advanced hepatic encephalopathy in a multicenter inpatient cirrhosis cohort. *Clinical Gastroenterology and Hepatology* 21: 1031-40; 2023
- 2023 Patel N, Silvey S, **O'Leary JG**, Morgan T, Patton H, Rogal S, Bajaj JS. Early Paracentesis is Associated with Better Prognosis Compared to Late or No-paracentesis in Hospitalized Veterans with Cirrhosis and Ascites. *Liver Transplantation* 29: 919-927; 2023.
- 2023 Bajaj JS, Lai JL, Tandon P, **O'Leary JG**, Wong F, Garcia-Tsao G, Vargas HE, Kamath PS, Biggins SW, Limon-Moro A, Shaw J, Mbach C, Chew M, Thacker LR, Reddy KR. Role of oral health, frailty, and minimal hepatic encephalopathy in the risk of hospitalization: A prospective multi-center cohort of outpatients with cirrhosis. *Clinical Gastroenterology and Hepatology*, 2023, 21: 1864-1872, 2023.
- 2023 Bajaj JS, Tandon P, **O'Leary JG**, Reddy KR, Garcia-Tsao G, Thuluvath PJ, Lai JC, Subramanian R, Vargas HE, Wong F, Fagan A, McGeorge S, Thacker LR, Kamath PS. Admission serum metabolites and thyroxine predict advanced hepatic encephalopathy in a multicenter inpatient cirrhosis cohort. *Clinical Gastroenterology and Hepatology*, 21: 103-1040, 2023.
- 2023 **O'Leary JG**, Farris AB, Gebel HM, Asrani SK, Askar M, Garcia V, Snipes GJ, Lo DJ, Knechtle SJ, Klintmalm GB, Demetris AJ. Detailed Analysis of Simultaneous Renal and Liver Allografts in the Presence of DSA. *Transplant Direct*. 9:e1500, 2023
- 2023 Lefaucheur C, Louis K, Morris AB, Taupin JL, Nickerson P, Tambur AR, Gebel HM, Reed EF; STAR 2022 Working Group. Clinical recommendations for posttransplant assessment of anti-HLA (Human Leukocyte Antigen) donor-specific antibodies: A Sensitization in Transplantation: Assessment of Risk consensus document. *Am J Transplant*. 23(1):115-132, 2023.
- 2022 Bajaj JS, Reddy KR, Tandon P, Garcia-Tsao G, Kamath PS, **O'Leary JG**, Wong F, Lai JL, Vargas HE, Thuluvath P, Subramanian R, Pena-Rodriguez M, Sikaroodi M, Thacker LR, Gilevert PM. Association of serum metabolites and gut microbiota at hospital admission with nosocomial infection development in patients with cirrhosis. *Liver Transplantation*, 2022, 28:1831-40, 2022.
- 2022 Bajaj JS, Wong F, Kamath PS, Lai JC, **O'Leary JG**. Acute-on-Chronic Liver Failure. *American Journal of Gastroenterology*, 117:831-34; 2022.
- 2022 Bajaj JS, **O'Leary JG**, Lai JC, Wong F, Long MD, Wong RJ, Kamath PS. Acute-on-Chronic Liver Failure Guidelines. *American Journal of Gastroenterology*, 117:225-52, 2022.
- 2022 Qian T, Fujiwara N, Koneru B, Ono A, Kubota N, Jajoriya AK, Tung MG, Crouchet E, Song WM, Marquez CA, Panda G, Hosida A, Raman I, Li QZ, Lewis C, Yopp A, Rich NE, Singal AG, Nakagawa S, Goossens N, Higasi T, Koh AP, Bian CB, Hoshida H, Tabrizian P, Gunasekaran G, Florman S, Schwartz ME, Hiotis SP, Nakahara T, Aikata H, Murakami E, Beppu T, Baba H, Warren R, Bhatia S, Kobayashi M, Kumada H, Fobar AJ, Parikh ND, Marrero JA, Rwema SH, Nair V, Patel M, Kim-Schulze S, Corey K, O'Leary JG, Klintmalm GB, Thomas DL, Dibas M, Rodriguez G, Zhang B, Firedman SL, Baumert TF, Fuchs BC, Chayama K, Zhu S, Chung RT, Hoshida Y. Molecular signature predictive of long-term liver fibrosis progression to inform antifibrotic drug development. *Gastroenterology* 162:1210-25, 2022.

- 2022 Wong F, Garcia-Tsao G, Reddy KR, **O'Leary JG**, Kamath PS, Tandon P, Lai JC, Vargas HE, Biggens SW, Fallon MB, Thuluvath PJ, Maliakkal BJ, Subramanian R, Thacker LR, and Bajaj JS. Prognosis in hospitalized patients with cirrhosis and acute kidney disease. *Liver International* 42:896-904, 2022.
- 2021 Bajaj JS, Guadalupe Garcia-Tsao G, Reddy KR, **O'Leary JG**, Hugo E Vargas HE, Lai JC, Kamath PS, Tandon P, Subramanian RM, Thuluvath P, Fagan A, Sehrawat T, de la Rosa Rodriguez R, Wong F. Specific urinary and serum metabolites on admission predict the development of AKI and the need for dialysis in hospitalized patients with cirrhosis. *Hepatology* 74:2699-713, 2021.
- 2021 **O'Leary JG**, Reddy KR, Tandon P, Biggins SW, Florence Wong F, Kamath PS, Garcia-Tsao G, Maliakkal B, Lai JC, Michael Fallon M, Vargas HE, Thuluvath P, Subramanian R, Thacker LR, and Bajaj JS. Increased Risk for ACLF and Inpatient Mortality in Hospitalized Patients with Cirrhosis and Hepatic Hydrothorax: The NACSELD experience. *Digestive Disease Sciences*, 66: 3612-8, 2021.
- 2021 Hu C, Anjur V, Saboo K, Reddy KR, **O'Leary JG**, Tandon P, Wong F, Garcia-Tsao G, Kamath PS, Lai JC, Biggins SW, Fallon MB, Thuluvath P, Subramanian RM, Maliakkal B, Vargas H, Thacker LR, Iyer RK, Bajaj JS. Artificial Intelligence and Prediction of Readmissions and Death in a Large Cohort of Patients with Cirrhosis. *American Journal of Gastroenterology* 116: 336-46, 2021.
- 2021 Wong F, Reddy KR, Tandon P, **O'Leary JG**, Garcia-Tsao G, Vargas H, Lai JC, Biggins S, Maliakkal B, Fallon M, Subramanian R, Thuluvath P, Kamath P, Thacker L, Bajaj J. The Natural History of Stages 2 & 3 Acute Kidney Injury in Patients with Decompensated Cirrhosis and Ascites. *Clinical Gastroenterology and Hepatology*, 19: 1661-9; 2021.
- 2021 Hasan MM, Nair SS, **O'Leary JG**, Thompson-Snipes L, Nyarige V, Wang J, Park W, Stegall M, Heilman R, Klintmalm GB, Joo H, Oh S. Implication of TIGIT<sup>+</sup> human memory B cells in immune regulation. *Nature Communications* 12: 1534; 2021.
- 2021 **O'Leary JG**, Philippe A, Freeman R, Heidecke H, Jennings LW, Catar R, Klintmalm GB, Dragun D. Non-HLA Autoantibodies at 1-year Negatively Impact 5-year Native Renal Function in Liver Transplant Recipients. *Transplantation Proceedings* 53:1019-24; 2021.
- 2021 Bajaj JS, **O'Leary JG**, Tandon P, Wong F, Kamath PS, Biggins SW, Garcia-Tsao G, Lai J, Fallon MB, Thuluvath PJ, Vargas HE, Maliakkal B, Subramanian RM, Thacker LR, Reddy KR. Insurance Status but Not Race or Ethnicity are Associated with Outcomes in a Large Hospitalized Cohort of Patients with Cirrhosis. *Clinical Gastroenterology and Hepatology*, 19:565-72; 2021
- 2020 Bajaj JS, Reddy KR, **O'Leary JG**, Vargas HE, Lai JC, Kamath PS, Tandon P, Wong F, Subramanian RM, Thuluvath P, Fagan A, White MB, Gavis EA, Kelly M, Sehrawat T, de la Rosa Rodriguez R, Garcia-Tsao G Serum levels of metabolites produced by intestinal microbes and lipid moieties independently associated with acute-on-chronic liver failure and death in patients with cirrhosis. *Gastroenterology*, 159: 1715-30, 2020.

- 2020 **O'Leary JG**, Tandon P, Reddy KR, Biggins SW, Wong F, Kamath PS, Garcia-Tsao G, Maliakkal B, Lai J, Fallon M, Vargas HE, Thuluvath P, Subramanian R, Thacker LR, **Bajaj JS**. Underutilization of Hospice in Inpatients with Cirrhosis: The NACSELD Experience. *Dig Dis Sci* 2020, 65:2571; 2020.
- 2020 Sarmast N, Kouznetsova M, Leise M, Bahirwani R, Maiwall R, Tapper E, Trotter J, Bajaj JS, Thacker L, Tandon P, Wong F, Reddy R, **O'Leary JG**, Masica A, Modrykamien A, Kamath PS, Sumeet A. Model for End-stage Liver Disease-Lactate and Prediction of Inpatient Mortality in Patients with Chronic Liver Disease. *Hepatology* 72: 1747; 2020.
- 2019 Haugen CE, McAdams-DeMarco M, Verna EC, Rahimi R, Kappus MR, Dunn MA, Volk ML, Gurakar A, Duarte-Rojo A, Ganger DR, **O'Leary JG**, Ladner D, Garonzik-Wang J, Segev DL, Lai JC. Body Mass Index, Frailty, and Waitlist Mortality: from the Multi-Center Functional Assessment in Liver Transplantation (FrAILT) Study. *JAMA Surgery*, 154: 1103-1109; 2019.
- 2019 Hasan MM, Thompson-Snipes L, Klintmalm GB, **O'Leary JG**, Oh S, Joo H. Functional characteristics of CD24<sup>hi</sup>CD38<sup>hi</sup> and CD24<sup>hi</sup>CD27<sup>+</sup> human regulatory B cells. *Journal of Immunology* 203: 2110-2120, 2019.
- 2019 Bajaj JS, **O'Leary JG**, Tandon P, Wong F, Kamath PS, Biggins SW, Garcia-Tsao G, Lai J, Fallon MB, Thuluvath P, Vargas HE, Maliakkal B, Subramanian RM, Thacker LR, Reddy KR. Targets to Improve Quality of Care for Patients with Hepatic Encephalopathy: Data from a Multi-Center Cohort. *Alimentary Pharmacology and Therapeutics* 49:1518-27; 2019.
- 2019 Bajaj JS, Tandon P, **O'Leary JG**, Wong F, Garcia-Tsao G, Kamath PS, Biggins SW, Lai JC, Vargas HE, Maliakkal B, Fallon MB, Thuluvath PJ, Subramanian RM, Thacker LR, K Reddy KR. Nosocomial infections are frequent and negatively impact outcomes in hospitalized patients with cirrhosis. *American Journal of Gastroenterology* 114:1091-1100; 2019.
- 2019 Wong F, Reddy KR, **O'Leary JG**, Tandon P, Biggins S, Garcia-Tsao G, Maliakkal B, Lai J, Fallon M, Vargas H, Subramanian R, Kamath P, Thacker L, Bajaj J. The impact of chronic kidney disease on outcomes in cirrhosis. *Liver Transplantation* 25: 870-90; 2019.
- 2019 Lai JC, Rahimi R, Verna EC, Kappus MR, Dunn MA, McAdams-DeMarco M, Haugen CE, Volk ML, Duarte-Rojo A, Ganger DR, **O'Leary JG**, Dodge JL, Ladner D, Segev D. Frailty is associated with waitlist mortality independent of ascites and hepatic encephalopathy: from the Multi-Center Functional Assessment in Liver Transplantation (FrAILT) Study. *Gastroenterology*, 156: 1675-1682, 2019.
- 2019 **O'Leary JG**, Bajaj JS, Tandon P, Biggins SW, Wong F, Kamath PS, Garcia-Tsao G, Maliakkal B, Lai J, Fallon M, Vargas HE, Thuluvath P, Subramanian R, Thacker LR, Reddy KR. Liver Transplant after Acute-on-Chronic Liver Failure (ACLF): The Multicenter NACSELD Experience. *Liver Transplantation*, 25: 571-579, 2019.
- 2019 Bajaj JS, Tandon P, **O'Leary JG**, Wong F, Biggins SW, Garcia-Tsao G, Kamath PS, Maliakkal B, Fallon MB, Lai JC, Thuluvath PJ, Vargas H, Subramanian RM, Thacker LR, Reddy KR. Outcomes in patients with cirrhosis on primary compared to secondary prophylaxis for spontaneous bacterial peritonitis. *American Journal of Gastroenterology*, 114: 599-606, 2019.

- 2019 Bajaj JS, Vargas HE, Reddy KR, Lai JC, **O'Leary JG**, Tandon P, Wong F, Robert R Mitrani, White MB, Kelly M, Myer D, Fagan A, Patil R, Sikaroodi M, PM Gillevet Association between intestinal microbiota collected at hospital admission and outcomes of patients with cirrhosis. *Clinical Gastroenterology and Hepatology*, 17: 756-65; 2019.
- 2018 Bajaj JS, Tandon P, **O'Leary JG**, Biggins SW, Wong F, Kamath PS, Garcia-Tsao G, Malaikkal B, Lai J, Fallon MB, Thuluvath P, Vargas H, Subramanian RM, Thacker LR, Reddy KR. The impact of albumin use on resolution of hyponatremia in hospitalized patients with cirrhosis. *Journal of Gastroenterology*, 113:1339-1344, 2018.
- 2018 Tambur AR, Campbell P, Claas FH, Feng S, Gebel HM, Jackson AM, Mannon RB, Reed EF, Tinkam K, Askar M, Chang P, Colvin M, Demetris J, Diamond J, Dipchand A, Fairchild R, Ford M, Friedewald J, Gill R, Glotz D, Goldberg H, Hachem R, Knechtle S, Kobashigawa J, Levine D, Levitsky J, Mengel M, Milford E, Newell K, **O'Leary JG**, Palmer S, Randhawa P, Smith J, Snyder L, Starling R, Sweet S, Taner T, Taylor C, Woodle S, Zeevi A and Nickerson P Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. *American Journal of Transplantation* 18:1604-14, 2018.
- 2018 Asrani SK, Saracino G, **O'Leary JG**, Gonzales S, Kim P, McKenna G, Klintmalm G, Trotter K. Recipient characteristics and morbidity and mortality after liver transplantation. *J Hepatology* 69:43-50, 2018.
- 2018 Robertson MJ, Soiban B, **O'Leary JG**, Sampaio LC, Taylor DA. Recellularization of rat liver: an in vitro model for assessing human drug metabolism and liver biology. *PLoS One* 13:e0191892, 2018.
- 2018 Bajaj JS, Reddy KR, Tandon P, Wong F, Kamath PS, Biggins SW, Garcia-Tsao G, Fallon MB, Malaikkal B, Lai J, Vargas HE, Subramanian RM, Thuluvath P, Thacker LR, **O'Leary JG**. Prediction of fungal infection development and their impact on survival using the NACSELD cohort. *American Journal of Gastroenterology* 113:556-563, 2018.
- 2018 **O'Leary JG**, Reddy KR, Garcia-Tsao G, Biggins SW, Wong F, Fallon MB, Subramanian RM, Kamath PS, Thuluvath P, Malaikkal B, Tandon P, Lai J, Thacker LR, Bajaj JS. NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. *Hepatology* 67:2367-74, 2018.
- 2018 Hezode C, Reau N, Svarovskaia ES, Doehle BP, Shanmugam R, Dvory-Sobol H, Hedskog C, McNally J, Osinusi A, Brainard DM, Miller MD, Mo H, Roberts SK, **O'Leary JG**, Shafran SD, Zeuzem S. Resistance analysis in patients with genotype 1-6 HCV infection treated with Sofosbuvir/Velpatasvir in the phase 3 studies. *Journal of Hepatology* 68:895-903, 2018.
- 2018 Bhutta A, Garcia-Tsao G, Reddy KR, Tandon P, Wong F, **O'Leary JG**, Acharya C, Banerjee D, Abalde J, Jones T, Shaw J, Deng Y, Ciarleglio M, Bajaj JS. Beta-blockers in hospitalized patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation. *Alimentary Pharmacology and Therapeutics* 47: 78-85; 2018.
- 2017 Spengler EK, **O'Leary JG**, Te HS, Rogal S, Pillai AA, Al-Osaimi A, Desai A, Fleming JN, Ganger D, Seetharam A, Tsoulfas G, Montenegro M, Lai JC. Liver Transplantation in the obese cirrhotic patient. *Transplantation* 101: 2288-2296; 2017.

- 2017 Saxena V, Khungar V, Verna EC, Levitsky J, Brown RS, Hassan MA, Sulkowski MS, **O'Leary JG**, Koraisky F, Galati JS, Kuo AA, Vainorius M, Akushevich L, Nelson DR, Fried MW, Terrault N, Reddy KR. Safety and Efficacy of Current DAA Regimens in Kidney and Liver Transplant Recipients with Hepatitis C: Results from the HCV-TARGET Study. *Hepatology* 66:1090-1101; 2017.
- 2017 Wong F, **O'Leary JG**, Reddy KR, Garcia-Tsao G, Fallon MB, Biggins SW, Subramanian R, Thuluvath PJ, Kamath PS, Patton H, Maliakkal B, Tandon P, Vargas H, Thacker L, Bajaj JS on behalf of The North American Consortium for Study of End-Stage Liver Disease (NACSELD). Acute Kidney Injury In Cirrhosis: Baseline Serum Creatinine Predicts Patient Outcomes. *American Journal of Gastroenterology* 112: 1103-1110; 2017.
- 2017 **O'Leary JG**, Demetris AJ, Philippe A, Freeman R, Cai J, Heidecke H, Smith C, Hart B, Jennings LW, Catar R, Everly M, Klintmalm GB, Dragun D. Non-HLA antibodies impact on C4d staining, stellate cell activation and fibrosis in liver allografts. *Transplantation* 101: 2399-2409; 2017.
- 2017 **O'Leary JG**, Smith C, Cai J, Banuelos N, Hart B, Jennings LW, Everly M, Klintmalm GB, Demetris AJ. Chronic AMR in liver transplant: Validation of the 1-year cAMR score's ability to determine long-term outcome. *Transplantation* 101: 2062-2070; 2017.
- 2017 JS Bajaj, **O'Leary JG**, Tandon P, Wong F, Garcia-Tsao G, Kamath PS, Maliakka B, Biggins SW, Thuluvath P, Fallon MB, Subramanian RM, Vargas HE, Lai J, Thacker LR, Reddy KR. Hepatic Encephalopathy Remains an Important Independent Determinant of Mortality in Cirrhosis: A Multi-Center NACSELD Experience. *Clinical Gastroenterology and Hepatology*, 15: 565-574, 2017.
- 2017 Younossi ZM, Stepanova M, Feld J, Zeuzem S, Sulkowski M, Foster GR, Mangia A, Charlton M, **O'Leary JG**, Curry MP, Nader F, Henry L, Hunt S. Sofosbuvir and Velpatasvir combination improve patient-reported outcomes in patients with HCV infection: From non-cirrhotics to those with compensated and decompensated cirrhosis. *Gastroenterology and Hepatology* 15:421-30; 2017.
- 2017 **O'Leary JG**, Wong F, Reddy R, Garcia-Tsao G, Kamath PS, Biggins SW, Fallon MB, Subramanian RM, Maliakkal B, Thacker L, Bajaj JS. Gender specific differences in baseline, peak and delta creatinine: The NACSELD experience. *Digestive Disease Sciences*, 62:668-76; 2017.
- 2017 **O'Leary JG**, Fontana R, Brown K, Burton JR, Firpi-Morell R, Muir A, O'Brien J, Rabinovitz M, Reddy R, Ryan R, Villadiego S, Prabhakar A, Brown RS. Efficacy and Safety of Simeprevir and Sofosbuvir With and Without Ribavirin in Subjects With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant: The Randomized GALAXY Study. *Transplant International*, 30: 196-208; 2017.
- 2017 Wadström J, Ericzon BG, Halloran PF, Bechstein WO, Opelz G, Serón D, Grinyó J, Loupy A, Kuypers D, Mariat C, Clancy M, Jardine AG, Guirado L, Fellström B, O'Grady J, Pirenne J, **O'Leary JG**, Aluvihare V, Trunečka P, Baccarani U, Neuberger J, Soto-Gutierrez A, Geissler EK, Metzger M, Gray M. Advancing Transplantation: New Questions, New Possibilities in Kidney and Liver Transplantation. *Transplantation*, 101; Suppl 2S: S1-41; 2017.
- 2017 Tandon P, Reddy KR, **O'Leary JG**, Garcia-Tsao G, Abraldes JG, Wong F, Biggins SW, Maliakkal B, Fallon MB, Subramanian RM, Thuluvath P,

- Kamath PS, Thacker LR, Bajaj JS; NACSELD: North American Consortium for the Study of End-Stage Liver Disease. A Karnofsky performance status-based score predicts death after hospital discharge in patients with cirrhosis. *Hepatology*, 65:217-24; 2017.
- 2016 Demetris AJ, Bellamy C, Hubscher SG, **O'Leary J**, Randhawa PS, Neil D, McCaughan G, DelBello A, Reinholt FP, Feng S, Haga H, Adeyi O, Fung JJ, Czaja AJ, Schiano T, Feil MI, Smith ML, Sebach M, Tanigawa RY, Yilmaz F. 2016 Comprehensive update of the Banff working group on liver allograft pathology: Introduction of antibody-mediated rejection. *American Journal of Transplantation*, 16: 2816-2835; 2016.
- 2016 Younossi ZM, Stepanova M, Charlton M, Curry MP, **O'Leary JG**, Brown RS, Hunt S. Patient-reported outcomes with sofosbuvir and velpatavir with or without ribavirin for hepatitis C related decompensated cirrhosis: an exploratory analysis from the randomized, open-label ASTRAL-4 phase 3 trial. *Lancet Gastroenterology Hepatology* 1: 122-132, 2016.
- 2016 Bajaj JS, Reddy KR, Tandon P, Wong F, Kamath PS, Garcia-Tsao G, Maliakkal B, Biggins SW, Thuluvath PJ, Fallon MB, Subramanian RM, Vargas H, Thacker L, **O'Leary JG**. The three-month readmission rate remains unacceptably high in a large North American cohort of cirrhotic patients. *Hepatology*, 64:200-8, 2016.
- 2016 Boyer TD, Sanyal AJ, Wong F, Lake JR, **O'Leary JG**, Ganger D, Jamil K, Stephen Chris Pappas SC. Reversal of Hepatorenal Syndrome Type 1 With Terlipressin: A Randomized, Double-Blind, Placebo-Controlled Study. *Gastroenterology*, 150:1579-89, 2016.
- 2016 Nadim MK, Durand F, Kellum JA, Levitsky J, **O'Leary JG**, Karvellas CJ, Bajaj JS; Davenport A, Jalan R, Angeli P, Caldwell SH, Fernández J, Francoz C, Garcia-Tsao G, Ginès P, Ison MG, Kramer R, Mehta RL, Moreau R, Mulligan D, Olson JC, Pomfret EA, Senzolo M, Steadman RH, Subramanian RM, Vincent JL, Genyk YS. Management of the Critically Ill Patient with Cirrhosis: A Multidisciplinary Perspective. *Journal of Hepatology*, 64:717-35, 2016.
- 2016 **O'Leary JG**, Cai J, Freeman R, Banuelos N, Hart B, Johnson M, Jennings LW, Kaneku H, Terasaki PI, Klintmalm GB, Demetris AJ. Proposed Criteria for Chronic Antibody Medicated Rejection in Liver Allografts. *American Journal of Transplantation*, 16: 603-14, 2016.
- 2016 Brown RS, **O'Leary JG**, Reddy KR, Kuo A, Morelli GJ, Burton JR Jr, Stravitz RT, Durand C, Di Bisceglie AM, Kwo P, Frenette CT, Stewart TG, Nelson DR, Fried MW, Terrault NA; HCV-TARGET Study Group. Interferon-free Therapy for Genotype 1 Hepatitis C in Liver Transplant Recipients: Real World Experience from HCV-TARGET. *Liver Transplantation* 2015, 22:24-33; 2016.
- 2015 Curry MP, **O'Leary JG**, Bzowej N, Muir AJ, Korenblat K, Fenkel JM, Reddy KR, Lawitz E, Flamm SL, Schiano T, Teperman L, Fontana R, Schiff E, Fried M, Doehle B, An D, McNally J, Osinusi A, Brainard DM, John G. McHutchison, Brown BS, Charlton M, for the ASTRAL-4 Investigators Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. *New England Journal of Medicine*, 373:2618-28, 2015.
- 2015 Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS, Fried M, Terrault N, **O'Leary JG**, Vargas H, Kuo A, Schiff E, Sulkowski M, Gilroy R, Watt K, Brown K, Kwo P, Pungpapong S, Korenblat K, Muir A, Teperman

- L, Fontana R, Denning J, Arterburn S, Brandt-Sarif T, Pang PS, McHutchison JG, Reddy KR, Afdhal N. Ledipasvir and Sofosbuvir for Hepatitis C in Patients with Advanced Liver Disease. *Gastroenterology*, 149:649-59, 2015.
- 2015 Verna EC, Saxena V, Burton JB, **O'Leary JG**, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS, Terrault NA. Telaprevir- and Boceprevir-based triple therapy for recurrent hepatitis C in liver transplant recipients with advanced disease: A multicenter study. *Transplantation*, 99:1644-51, 2015.
- 2015 Reddy KR, **O'Leary JG**, Kamath PS, Fallon M, Biggins S, Wong F, Patton H, Garcia-Tsao G, Subramanian R, Thacker L, Bajaj J. High risk of delisting or death in liver transplant candidates following infections: Results from NACSELD. *Liver Transplantation*, 21:881-8, 2015.
- 2015 **O'Leary JG**, Kaneku H, Banuelos N, Jennings LW, Klintmalm GB, Terasaki PI. Impact of IgG3 subclass and C1q-fixing donor specific antibodies on rejection and survival in liver transplantation. *American Journal of Transplantation*, 15:1003-13, 2015.
- 2015 Keating BJ, van Setten J, Jacobson PA, Holmes MV, Verma SS, Chandrupatla HR, Nair N, Gao H, Li Y, Chang BL, Wong C, Phillips R, Cole BS, Mukhtar E, Zhang W, Cao H, Mohebnasab M, Hou C, Lee T, Steel L, Shaked O, Garifallou J, Miller MB, Karczewski KJ, Akdere A, Lloyd K, McGinn D, Michaud Z, Colasacco A, Lek M, Fu Y, Pawashe M, Guettouche T, Himes A, Perez L, Wu B, Schladt D, Menon M, Zhang Z, Traganet V, de Jonge N, Otten HG, de Weger RA, van de Graaf EA, Baan CC, Manintveld OC, Vlaminc ID, Piening BD, Strehl C, Shaw M, Snieder H, Klintmalm GB, **O'Leary JG**, Amaral S, Goldfarb S, Rand E, Rossano JW, Kohli U, Heeger P, Stahl E, Christie JD, Fuentes MH, Levine JE, Aplenc R, Schadt EE, Stanger BE, Kluin J, Potena L, Zuckermann A, Khush K, Alzahrani AJ, Al-Muhanna FA, Al-Ali A, Al-Ali R, Al-Rubaish AM, Al-Mueilo S, Byrne EM, Miller D, Alexander SI, Onengut-Gumuscu S, Rich SS, Suthanthiran M, Tedesco H, Saw CL, Ragoussis J, Kfoury AG, Horne B, Carlquist J, Gerstein MB, Reindl-Schwaighofer R, Oberbauer R, Wijmenga C, Palmer S, Pereira AC, Segovia J, Alonso-Pulpon LA, Comez-Bueno M, Vilches C, Jaramillo N, de Borst MH, Naesens M, Hao K, MacArthur DG, Balasubramanian S, Conlon PJ, Lord GM, Ritchie MD, Snyder M, Olthoff KM, Moore JH, Petersdorf EW, Kamoun M, Wang J, de Bakker PIW, Hakonarson H, Murphy B, Lankree MB, Garcia-Pavia P, Oetting WS, Birdwell KA, Israni AK, Shaked A, Asselbergs FW. Design and implementation of the international genetics and translational research in transplantation network. *Transplantation*, 99:2401-12, 2015.
- 2015 Camos-Varela I, Lai JC, Verna EC, **O'Leary JG**, Stravitz RT, Forman LM, Trotter JF, Brown RS, Terrault NA. Hepatitis C Genotype Influences Recurrent Disease Outcomes Following Liver Transplantation. *Transplantation*, 99:835-40.
- 2015 **O'Leary JG**, Reddy KR, Wong F, Kamath PS, Patton HM, Biggins SW, Fallon MB, Garcia-Tsao G, Subarmanina RM, Malik R, Thacker LR, Bajaj JS. Long-term antibiotic and proton-pump inhibitor use strongly predict subsequent infections in cirrhosis: A prospective multi-center study. *Clinical Gastroenterology & Hepatology*, 13: 753-9, 2015.
- 2015 Curry MP, Forns X, Chung RT, Terrault NA, Brown R, Fenkel JM, Gordon F, **O'Leary JG**, Kuo A, Schiano T, Everson G, Schiff E, Befeler A, Gane E,



- Saab S, McHutchison JG, Subramanian GM, Symonds WT, Denning J, McNair L, Arterburn S, Svarovskaia E, Moonka D, Afdhal N. *Gastroenterology*, 148:100-107, 2015.
- 2014 **O'Leary JG**. Debate – A bridge too far: NAFLD will not exhaust the donor pool. *Liver Transplantation*, 20:S38-41, 2014.
- 2014 **O'Leary JG**, Shiller SM, Bellamy C, Nalesnik MA, Kaneku H, Jennings LW, Isse K, Terasaki PI, Klintmalm GB, Demetris AJ. Acute Liver Allograft Antibody-Mediated Rejection: an inter-institutional study of significant histopathological features. *Liver Transplantation*, 20: 1244-55, 2014.
- 2014 Burton JR, **O'Leary JG**, Verna EC, Saxena V, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS, Terrault NA. A US Multicenter Study of Hepatitis C Treatment of Liver Transplant Recipients with Protease-Inhibitor Triple Therapy Article. *Journal of Hepatology*, 61:508-14, 2014.
- 2014 Bajaj JS, **O'Leary JG**, Reddy KR, Wong F, Biggins SW, Patton H, Fallon MB, Garcia-Tsao G, Maliakkal B, Malik R, Subramanian RM, Thacker LR, Kamath PS. Survival in Sepsis-Related Acute-on-Chronic Liver Failure is Defined by Extra-Hepatic Organ Failures. *Hepatology*, 60: 250-6, 2014.
- 2014 **O'Leary JG**, Kaneku H, Jennings LW, Susskind BM, Terasaki PI, Klintmalm GB. Donor-Specific Alloantibodies are Associated with Fibrosis Progression after Liver-Transplantation in HCV-Infected Patients. *Liver Transplantation*, 20, 655-63; 2014.
- 2014 **O'Leary JG**, Demetris AJ, Friedman LS, Gebel HM, PF Halloran PF, Kirk AD, Knechtle SJ, McDiarmid SV, Shaked A, Terasaki PI, Tinckam KJ, Tomlanovich SJ, Wood KJ, Woodle ES, Zachary AA, GB Klintmalm GB. The Role of Donor-Specific HLA Alloantibodies in Liver Transplantation. *American Journal of Transplantation*, 14: 218-27, 2014.
- 2014 **O'Leary JG**, Kaneku H, Demetris AJ, Marr JD, Shiller SM, Susskind BM, Tillery W, Terasaki PI, Klintmalm GB. Antibody Mediated Rejection As a Contributor to Previously Unexplained Early Liver Allograft Loss. *Liver Transplantation*, 20: 218-227; 2014.
- 2013 Wong F, **O'Leary JG**, Reddy KR, Patton H, Kamath PS, Fallon MB, Garcia-Tsao G, Subramanian RM, Malik R, Maliakkal B, Thacker LR, Bajaj JS. Validation of the New Consensus Definition of Acute Kidney Injury in Predicting Mortality in Infected Cirrhotic Patients. *Gastroenterology* 145: 1280, 2013.
- 2013 **O'Leary JG**, Kaneku H, Jennings LW, Bañuelos N, Susskind BM, Terasaki PI, Klintmalm GB. Preformed Class II Donor Specific Alloantibodies Increase the Risk of Early Rejection After Liver-Transplantation. *Liver Transplantation* 9: 973-80, 2013.
- 2013 Kaneku H, **O'Leary JG**, Bañuelos N, Jennings LW, Susskind BM, Klintmalm GB, Terasaki PI. *De novo* donor-specific HLA antibodies decrease patient and graft survival in 1,099 consecutive liver transplant recipients. *American Journal of Transplantation* 13; 1541, 2013.
- 2013 Michael M, Campbell P, Gebel H, Randhawa P, Rodriguez R, Colvin R, Conway J, Hachem R, Halloran P, Keshavjee S, Nickerson P, Murphey C, **O'Leary J**, Reeve J, Tinckam K, Reed EF. Meeting Report: 2012 CST-AST JOINT SESSION: Precision Diagnostics in Transplantation: From Bench to Bedside. *American Journal of Transplantation* 13:562-8; 2013.

- 2013 **O'Leary JG**, Gebel HM, Ruiz R, Bray RA, Marr J, Zhou XJ, Shiller SM, Susskind BM, Kirk AD, Klintmalm GB. Class II Alloantibody and Mortality in Simultaneous Liver-Kidney Transplantation. *American Journal of Transplantation*13:954-60, 2013.
- 2012 Bajaj J, **O'Leary JG**, Reddy KR, Olson JC, Wong F, Brown G, Subramanian R, Malik R, Thacker LR, Noble NA, Kamath PS. In-hospital Mortality in Cirrhosis is Related to Nosocomial Infections Independent of MELD Score: The North American Consortium for the Study of End-Stage Liver Disease (NACSELD) Study. *Hepatology*56:2328-35; 2012.
- 2012 Paterno F, Shiller M, Tillery G, **O'Leary J**, Susskind B, J. Trotter J, Klintmalm GB. Bortezomib for Acute Antibody-Mediated Rejection in Liver Transplantation. *American Journal of Transplantation*12:2526-31, 2012.
- 2012 **O'Leary JG**, Neri MA, Trotter JF, Davis GD, Klintmalm GB. Transplantation of Hepatitis C Antibody Positive Livers: Genotype 1 Usually Dominates. *Transplant International* 25: 825-9; 2012.
- 2012 Kaneku H, **O'Leary JG**, Taniguchi M, Susskind BM, Terasaki PI, Klintmalm GB. Donor-Specific HLA Antibodies of Multiple IgG Subclasses are associated with Chronic Rejection after Liver Transplantation. *Liver Transplantation*18: 984-92, 2012.
- 2012 Lai JC, **O'Leary JG**, Trotter JF, Verna EC, Brown RS, Stravitz RT, Duman JD, Forman LM, Terrault NA. Risk of Advanced Fibrosis with Grafts from Hepatitis C Antibody Positive Donors: A Multicenter Cohort Study. *Liver Transplantation*18:532-538, 2012.
- 2012 Saxena V, Lai JC, **O'Leary JG**, Verna EC, Brown RS, Stravitz RT, Trotter JF, Krishnan K, Terrault NA. Donor-Recipient Race Mismatch in African-American Liver Transplant Patients with Chronic Hepatitis C. *Liver Transplantation*18:524-531, 2012.
- 2011 McKenna GJ, Trotter JF, Klintmalm E, Onaca N, Ruiz R, Jennings LW, Neri M, **O'Leary JG**, Davis GL, Levy MF, Goldstein RM, Klintmalm GB. Limiting hepatitis C virus progression in liver transplant recipients using sirolimus based immunosuppression. *American Journal of Transplantation* 11:2379-87, 2011.
- 2011 **O'Leary JG**, Kaneku H, Susskind BM, Jennings LW, Davis GL, Klintmalm GB, Terasaki PI. Anti-HLA donor specific antibodies found in nearly all patients with chronic rejection post-liver transplant. *American Journal of Transplantation* 11:1868-76, 2011.
- 2011 Lai JC, Verna EC, Brown RS, **O'Leary JG**, Trotter JF, Forman LM, Duman JD, Foster RG, Stravitz RT, Terrault NA. Hepatitis C Virus Infected Females Have a Higher Risk of Advanced Fibrosis and Graft Loss after Liver Transplantation than Males. *Hepatology* 54:418-24, 2011.
- 2011 **O'Leary JG**, Landaverde C, Jennings L, Goldstein RM, Davis GL. NASH/cryptogenic cirrhosis patients are less likely than hepatitis C patients to receive a liver transplant. *Clinics in Gastroenterology and Hepatology* 9:700-704, 2011.
- 2011 **O'Leary JG**, Trotter JF, Neri MA, Jennings LW, McKenna GJ, Davis GL, Klintmalm GB. Effect of tacrolimus on survival in hepatitis C-infected patients after liver transplantation. *Baylor Proceedings*24:187-191, 2011.
- 2009 **O'Leary JG**, Rees CR, Klintmalm GB, Davis GL. IVC Stent Resolves Hepatopulmonary Syndrome in an Adult with a Spontaneous IVC-Portal Vein Shunt. *Liver Transplantation*15:1897-900, 2009.

- 2009 **O'Leary JG**, Davis GL. Conivaptan Increases Serum Sodium in Hyponatremic Patients with End Stage Liver Disease. *Liver Transplantation* 15:1325-9, 2009.
- 2009 **O'Leary JG**, Randall H, Onaca N, Jennings L, Klintmalm GB, Davis GL. Post-Liver Transplant Survival in Hepatitis C Patients is Improving Over Time. *Liver Transplantation* 15:360-8, 2009.
- 2008 **O'Leary JG**, Zachary K, Misdraji J, Chung RT. De novo autoimmune hepatitis during immune reconstitution in an HIV-infected patient receiving highly active antiretroviral therapy. *Clin Infect Dis*.46:e12-4, 2008.
- 2007 **O'Leary JG**, Chan JL, McMahon CM, Chung RT. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. *Hepatology*45:895-898, 2007.
- 2006 **O'Leary JG**, Goodarzi M, Drayton, DL, von Andrian, UH: T and B cell-independent adaptive immunity mediated by natural killer cells. *Nature Immunology*.7: 507-516, 2006.
- 2004 **O'Leary J**, Chung RT: New antiviral therapies for hepatitis C. *Expert Rev. Anti Infective Ther*. 2: 235–243, 2004.
- 1994 Wender PA, Beckham S, **O'Leary JG**: A Second-Generation Photochemically Activatable Dynemicin Analog: A Concise Synthesis and DNA Cleavage Studies. *Synthesis*, Special Issue: 1278-1282, 1994.

#### **Book Chapters:**

- 2015 **O'Leary JG**, Trotter JF. Late Complications of Liver Transplantation. *Liver Transplantation*. 2015
- 2011 **O'Leary JG**, Friedman LS. Surgery in the patient with liver disease and postoperative jaundice. *Handbook of Liver Disease*.403-419, 2011.
- 2010 **O'Leary JG**, Davis GL. Hepatitis C. *Sleisenger and Fordtran's Gastrointestinal and Liver Disease*, 9<sup>th</sup> edition.
- 2009 **O'Leary JG**, Yachinski PS, Friedman LS. Surgery in the patient with liver disease. *Clinics in Liver Disease*13:211-31, 2009.
- 2005 **O'Leary JG**, Friedman LS: Management of the Surgical Patient with Liver Disease. In Murphy K, Ray M (eds): Medical Management of the Surgical Patient. pp349-392.
- 2004 **O'Leary JG**, Friedman LS: Acute and chronic viral hepatitis. In Rakel RE, Bope ET (eds): Conn's Current Therapy. Philadelphia, Elsevier Saunders, 2005, p 605-613.

#### **Reviews:**

- 2021 **O'Leary JG**. ACLF and Liver Transplantation. *Current Treatment Options in Gastroenterology* 19:473-82, 2021.
- 2020 Aday A, **O'Leary JG**. Acute-on-Chronic Liver Failure: Definitions and Implications. *Clinics in Liver Disease* 24: 521-534; 2020.
- 2019 **O'Leary JG**, Greenberg CS, Patton HM, Caldwell SH. Practice Guidelines: Coagulation in Cirrhosis. *Gastroenterology* 157:34-43; 2019.
- 2016 **O'Leary JG**, Levitsky J, Wong F, Nadim MK, Charlton M, Kim WR. Protecting the kidney in liver transplant candidates Practice-Based Recommendations from the American Society of Transplantation Liver and Intestine Community of Practice. *American Journal of Transplantation*, 16:2516-31, 2016.

E-mail: dr\_jackieo@yahoo.com

Phone: 469-271-7829

- 2016 Levitsky J, **O'Leary JG**, Asrani S, Sharma P, Fung J, Wisemen A, Niemann. Protecting the kidney in liver transplant recipients Practice-Based Recommendations from the American Society of Transplantation Liver and Intestine Community of Practice. *American Journal of Transplantation*, 2531-44, 2016.
- 2016 Kim PTW, Demetris AJ, **O'Leary JG**. Prevention and Treatment of Liver Allograft Antibody Medicate Rejection and the Role of the "2-Hit Hypothesis". *Current Opinion in Transplantation*, 21:209-18, 2016.
- 2016 **O'Leary JG**, Samaniego M, Barrio MC, Potena L, Zeevi A, Djamali A, Cozzi E. The influence of immunosuppressive agents on the risk of de novo donor-specific HLA antibody production in solid organ transplant recipients. *Transplantation*, 100: 39-53, 2016.
- 2015 **O'Leary JG**, Orloff SL, Levitsky J, Martin P, Foley DP. Keeping high MELD liver transplant candidates alive. *Liver Transplantation*, 21:1428-1437, 2015.
- 2015 Verna EC, **O'Leary JG**. Hepatitis C treatment in patients on the liver transplant waiting list. *Current Opinion in Transplantation*, 20:242-50, 2015.
- 2015 Demetris AJ, Zeevi A, **O'Leary JG**. ABO-compatible liver allograft antibody mediated rejection: an update. *Current Opinion in Transplantation*, 20:314-24, 2015.
- 2015 Rahimi RS, **O'Leary JG**. Post-Liver Transplant Hepatitis C Therapy. *Current Treatment Opinions in Gastroenterology*.13: 249-58, 2015.
- 2014 Asrani S, **O'Leary JG**. Acute-on-Chronic Liver Failure. *Clinics in Liver Disease*. 18: 561-74; 2014
- 2013 **O'Leary JG** & Klintmalm GB. Impact of Donor-Specific Antibodies on Results of Liver Transplantation. *Current Opinion in Transplantation* 18:279; 2013.
- 2012 Bajaj J, **O'Leary JG**, Wong F, Reddy R, Kamath PS. Bacterial infections in end stage liver disease: Current challenges and future directions. *GUT* 61:1219-25; 2012.
- 2011 **O'Leary JG**, Davis GL. HCV and Chemotherapy: Does Infection Change Management? *Current Hepatitis Reports*11:34-40; 2012.
- 2010 **O'Leary JG**, Davis GL HCV virus replication and potential targets for direct acting agents. *Therapeutic Advances in Gastroenterology*3:43-53, 2010.
- 2008 **O'Leary JG**, Lepe ML, Davis GL. Indications for liver transplantation. *Gastroenterology* 134:1764-76, 2008.
- 2007 **O'Leary JG**, Pratt DS. Cholestasis and cholestatic syndromes. *Current Opinion in Gastroenterology* 23:232-236, 2007
- 2006 **O'Leary JG**, Chung RT. Management of HIV/HCV-coinfection. *The AIDS Reader*.16:313-320, 2006.

#### **Editorials:**

- 2025 Amin AM & **O'Leary JG**. To Recover or Not to Recover from ACLF: Ask the Monocytes. *Hepatology* 2024, 81:396-398; 2025. PMID 38950406.
- 2024 Tsai SY & **O'Leary JG**. Let's Pump You Up! *Hepatology*, 2024, 80:508-10; 2024, 80:508-10; 2024, PMID 38836631.
- 2024 Tsai SY & **O'Leary JG**. Optimizing Outcomes in Patients with Ascites Complicating Cirrhosis- Maximizing The Hour of Power. *Digestive Diseases & Science*, 69:1080-2; 2024; PMID 38217677.

E-mail: dr\_jackieo@yahoo.com

Phone: 469-271-7829

- 2019 **O'Leary JG**. Portal Vein Thrombosis Prediction: Re-balanced coagulation and rethinking anticoagulation. *Liver Transplantation*, 12:1741-2; 2019.
- 2018 Aday AW, **O'Leary JG**. DSA's meaningful impact on liver transplantation. *Liver Transplantation*, 24:999-1000, 2018.
- 2017 **O'Leary JG**. Tacrolimus: How low can you go? *Alimentary Pharmacology and Therapeutics*, 46: 66-68, 2017.
- 2016 Rahimi RS & **O'Leary JG**. Transfusing common sense instead of blood products into coagulation testing in patients with cirrhosis: Overtreatment ≠ Safety. *Hepatology*, 63:368-70, 2016.
- 2015 **O'Leary JG**. Donor-specific alloantibodies in liver transplantation: How do we define and improve long-term success? *Transplant International* 28:1359-61, 2015.
- 2015 Asrani SK & **O'Leary JG**. Can one pill a day keep rejection away? *American Journal of Transplantation*, 15:1135-6, 2015.
- 2015 Asrani SK, **O'Leary JG**. The changing liver transplant waitlist: An emerging liver purgatory? *Gastroenterology*, 148: 493-6, 2015.
- 2012 Davis GL, **O'Leary JG**. Advances in Hepatology: Use of protease inhibitors in liver transplant recipients. *Gastroenterology & Hepatology* 8: 183-4, 2012.
- 2011 **O'Leary JG**, Trotter JT. Is MELD fit enough? *Gastroenterology* 140:1871-1874, 2011
- 2007 **O'Leary JG**, Friedman, LS. Predicting Surgical Risk in Patients With Cirrhosis: From Art to Science. *Gastroenterology* 132:1609-1611, 2007.

#### Letters to the Editor:

- 2024 Barnard Giustini A, Patel A, Cheung R, Nobbe A, Perumalswami P, Johnson R, Jakob S, Patton H, Morgan T, **O'Leary JG**, Bajaj JS, Rogal S. Survey of attitudes and knowledge of early paracentesis guidelines and performance in providers in the Veterans Health Administration. *Liver Transplantation*, 30:E48-9, 2024, PMID 38920367.
- 2022 **O'Leary JG** & Bajaj JS. MELD 3.0: One small step for womankind or one big step for everyone? *Gastroenterology*, 162:1780-1, 2022.
- 2021 Bajaj JS, Garcia-Tsao G, Kamath PS, **O'Leary JG**, Reddy R, Wong F. *Hepatology*, 74: 2916-7, 2021.
- 2019 Wong F, Reddy KR, **O'Leary JG**, Garcia-Tsao G, Kamath PS, Bajaj JS. *Liver Transplantation*, 10: 1586-7; 2019.
- 2018 **O'Leary JG**, Reddy KR, Kamath PS, Wong F Garcia-Tsao G, Thacker LS, Bajaj JS. *Hepatology* 68: 2046-48, 2018.
- 2018 **O'Leary JG**, Reddy KR, Kamath PS, Wong F Garcia-Tsao G, Bajaj JS. ACLF Prognostication: Complex ≠ Better. *Hepatology* 2018, 68: 791, 2018.
- 2016 Levitsky J, Verna EC, **O'Leary JG**, Bzowej NH, Moonka DK, Hyland RH, Arterburn S, Dvory-Sobol H, Brainard DM, McHutchison JG, Terrault NA. Perioperative Ledipasvir-Sofosbuvir for HCV in Liver Transplant Recipients. *New England Journal of Medicine*, 375: 21-23; 2016.
- 2015 Bajaj JS, **O'Leary JG**, Wong F, Kamath PS. Variations in Albumin Use in Patients with Cirrhosis: An AASLD Survey. *Hepatology*, 62: 1923-4, 2015.
- 2015 **O'Leary JG**, Bajaj JS. Reply. *Clinical Gastroenterology and Hepatology*, 13: 2028; 2015.

E-mail: dr\_jackieo@yahoo.com

Phone: 469-271-7829

- 2015 Wong F, **O'Leary JG**, Reddy KR, Kamath PS, Garcia-Tsao G, Thacker L, Bajaj J.A serum creatinine of 1.5mg/dL for AKI – To be or not to be. *J Hepatology*, 62:741-3, 2015.
- 2013 **O'Leary JG**, McKenna G, Klintmalm GB, Davis GD. The Effect of Telaprevir on the Pharmacokinetics of Sirolimus in Liver Transplant Recipients. *Liver Transplantation* 19:463-5, 2013.

#### **Editorial Positions:**

- 2021- Present Associated Editor, Hepatology  
2015-2020 Editorial Board, Liver Transplantation  
2014-2021 Associate Editor, The American Journal of Transplantation

#### **Committee Service:**

- 2024-Present Hepatology National VA Field Advisory Board Member  
2024-Present Hepatology National VA Sub-FAB Chair for Cirrhosis  
2023-Present Abstract review Chair AASLD: ACLF  
2023-Present AASLD Portal Hypertension SIG member  
2022-2023 Abstract reviewer ATC Biomarkers: Abdominal  
2021-2024 Hepatology National VA Field Advisory Board Sub-FAB Co-Chair for Cirrhosis  
2020-Present UTSW GI Fellowship Program Evaluation Committee  
2019-2022 ILTS Transplant Immunology SIG Executive committee  
2017-Present Advanced Liver Disease National VA Committee  
2017-2020 HIT VISN HCV Committee  
2017-2020 AASLD Abstract review chair for ACLF  
2016-2019 AST Elected Member-at-Large of the AST Liver and Intestine Community of Practice  
2014-2017 Chair AST Workgroup to Explore Liver Redistricting  
2014-2017 AASLD Elected Member-at Large of the Liver Transplant and Surgery SIG  
2014-2016 ILTS Abstract Reviewer  
2014-2016 Appointed member of the AASLD Practice Guidelines Committee  
2014-2016 ILTS Vanguard Committee  
2014-2016 Appointed member of the ILTS Basic Science Committee  
2014-2016 AST Elected Co-Chair of the AST Liver and Intestine Community of Practice  
2014 CDC Clinical laboratory improvement advisory committee virtual crossmatch working group meeting invited member.  
2013-2023 AASLD Liver Transplantation and Surgery SIG member  
2013-2016 Liver Councilor on the Board, Texas Transplantation Society  
2013-2015 AST - WTC Abstract Review Co-Chair for Chronic Liver Failure  
2013-2014 AST LICOP Education Committee Liaison  
2013-2014 Texas Transplantation Society Program Committee  
2012-2015 AASLD Elected Member-at Large of the Acute-on-Chronic Liver Failure Special Interest Group  
2012-2014 AST Elected Member-at Large of the AST Liver and Intestine Community of Practice  
2011-2015 AASLD Abstract review chair for HCV Therapy: Preclinical and Early Clinical Development  
2010-Present AST Liver and Intestinal Community of Practice Committee Member

E-mail: dr\_jackieo@yahoo.com

Phone: 469-271-7829

### **Research Committees Leadership Roles:**

2024-Present PRECIOSA publications steering committee  
2014-2018 HCV Target Post-Transplant Writing Group Steering Committee  
2014-2016 GS-US-342-1137 Phase 3 Multicenter Trial External Advisory Board  
2012-Present NACSELD Steering Committee

### **Professional Memberships:**

2020-Present American College of Gastroenterology  
2013-2017 Texas Transplantation Society  
2012-Present The Transplantation Society Member  
2012-Present European Association for the Study of the Liver Member  
2009-Present American Society of Transplantation Member  
2009-Present International Liver Transplant Society Member  
2005-Present American Association for the Study of Liver Disease Member  
2002-Present American Gastrointestinal Association Member

### **Grants**

**VA New Investigator Grant** **O'Leary (PI)** 9/18-9/20  
Defining the role of rosuvastatin in improving liver fibrosis and inflammation in nonalcoholic stetohepatitis.

### **Investigator Initiated Trials:**

**O'Leary (Site-PI)** 2020-Present  
Overall PI (Jasmohan Bajaj, VCU)  
To evaluate the natural history of infections and other complications of cirrhosis in a multi-center North American Study (NACSELDIII).  
Salix Pharmaceuticals and Sequana

**O'Leary (Site-PI)** 2016-2017  
Functional assessment in liver transplant candidates (FrAILT).  
NIH

**O'Leary (PI)** 2015-2017  
iGeneTRaiN, 800,000 SNP chip analysis of genomics in donor-recipient pairs to evaluate risk for a variety of factors in liver transplant.  
University of Pennsylvania/Baylor Foundation

**O'Leary (Site PI)** 2015-2017  
Donor specific antibodies and risk of late-onset PTLT in liver recipients.  
NIH

**O'Leary (PI)** 2015-2017  
Role of regulatory B cells in liver transplant patients.  
Sangkong Oh at Baylor Institute for Immunologic Research

**O'Leary (Sub-I)** 2015-2017  
Serum/plasma proteomics for discovery and validation of biomarkers for chronic kidney disease in liver transplant patients.

E-mail: dr\_jackieo@yahoo.com  
Phone: 469-271-7829  
NIH

**O'Leary (PI)** 2014-2017  
A Phase 2 open-label study in patients with recurrent Genotype 1 hepatitis C postorthotopic Liver transplant to explore the safety and efficacy of simeprevir and sofosbuvir with and without ribavirin (GALAXY)  
Janssen Research & Development Multicenter Trial

**O'Leary (Site PI)** 2014-2017  
Retrospective study to validate a specific microRNA biomarker panel for rejection in liver transplant recipients.  
Avi Shaked at University of Pennsylvania

**O'Leary (Site PI)** 2014-2017  
Retrospective study to validate a specific mRNA biomarker signature for rejection in liver transplant recipients.  
Dan Solomon, Josh Levitsky, Mike Abecassis at Northwestern

**O'Leary (PI)** 2014-2020  
Identifying the Role of Angiotensin-1 Receptor Donor Specific Alloantibodies in Liver Transplantation.  
Duska Dragun

**O'Leary (Site PI)**  
Boceprevir or Telaprevir with Pegylated Interferon and Ribavirin therapy in liver transplant recipients with recurrent hepatitis C.  
CRUSH-C

**O'Leary (Site-PI)** 2014-2017  
The estimated costs of HCV therapy in liver transplant in recipients: retrospective multicenter cost-effectiveness evaluation.  
Gilead

**O'Leary (Site PI)** 2013-2017  
Identify a gene signature of rapid fibrosis progression in patients' 1-year protocol liver biopsy transplanted for HCV.  
Ray Chung, Massachusetts General Hospital

**O'Leary (PI)** 2013-2017  
Donor-Specific Antibodies in Liver Transplantation, Overall PI (Jacqueline O'Leary, BUMC)  
To evaluate the natural history of preformed and *de novo* DSA in liver transplant and simultaneous liver-kidney transplant recipients.  
Fisher Scientific

**O'Leary (Sub-I)**  
Quantitative liver function tests using HEPQUANT.  
University of Colorado

**O'Leary (Site PI)** 2013-2017



E-mail: dr\_jackieo@yahoo.com

Phone: 469-271-7829

Infections and Other Complications of Cirrhosis, Overall PI (Jasmohan Bajaj, VCU)

To evaluate the natural history of infections and other complications of cirrhosis in a multi-center North American Study.

Grifols Pharmaceuticals

**O'Leary (PI)**

2011-2-14

Rejection as an Unrecognized Cause of Primary Graft Non-function after Liver Transplantation  
Funded by Terasaki Foundation Laboratory

**O'Leary (PI)**

2011-2013

Analysis of (non-HLA DSA) antibodies in post liver transplant patients with chronic rejection to correlate them with patient outcomes

Peter Stazney, UTSW

**O'Leary (PI)**

2011-2014

Evaluation of rapamycin pharmacokinetics in telaprevir treated patients with a liver transplant.  
Baylor Foundation

**O'Leary (PI)**

2010-2013

Analysis of antibodies in post liver transplant patients with chronic rejection and correlate with patient outcomes.

Funded by Terasaki Foundation Laboratory

**O'Leary (PI)**

2010-2017

Donor-specific alloantibodies in liver transplantation or simultaneous liver-kidney transplantation.

Baylor Foundation

**O'Leary (PI)**

2009-2011

Analysis of antibodies in post-liver transplant patients with chronic rejection and correlate with patient outcomes.

One Lambda

**O'Leary (PI)**

2009-2011

The effect of alloantibody specificity on outcome in allosensitized recipients of simultaneous liver kidney transplants.

Baylor Foundation and Emory University

#### **Pharmaceutical Sponsored Trials:**

##### **River-2-Renal**

**O'Leary (Site PI)**

5/24-Present

River 2 Renal - A Single-blind, Phase 2, Multi-center, Randomized Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the Relaxin Agonist R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients with Hepatorenal Syndrome – Acute Kidney Injury

##### **Madrigal**

**O'Leary (Site PI)**

1/24-Present

MAESTRO-NASH OUTCOMES - A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients with Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis

##### **Salix**

**O'Leary (Site PI)**

1/23-Present

E-mail: dr\_jackieo@yahoo.com

Phone: 469-271-7829

RNLC3131: A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of Rifaximin soluble solid dispersion (SSD) tablets for the delay of encephalopathy decompensation in cirrhosis (RED-C).

<b>Grifols</b> PRECIOSA trial	<b>O'Leary (Site PI)</b>	2/19-1/24
----------------------------------	--------------------------	-----------

<b>Mallinckrodt</b> CONFIRM trial	<b>O'Leary (Site PI)</b>	8/18-12/19
--------------------------------------	--------------------------	------------

	<b>O'Leary (Site PI)</b>	7/14-3/16
--	--------------------------	-----------

A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection and Child-Pugh Class B Cirrhosis  
Gilead Sciences Multicenter Trial

	<b>O'Leary (Site PI)</b>	6/14-2017
--	--------------------------	-----------

Open-label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adult Liver Transplant Recipients with Genotype 1 Hepatitis C Virus (HCV) Infection  
Abbott Industries Multicenter Trial

	<b>O'Leary (Site PI)</b>	2/14-2017
--	--------------------------	-----------

A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection and Chronic Kidney Disease  
Merck Multicenter Trial

	<b>O'Leary (Site PI)</b>	2014-2017
--	--------------------------	-----------

A long-term follow up study to evaluate the durability to virologic response and/or viral resistance patterns of subjects with chronic hepatitis C who have been previously treated with MK-5172 in a prior clinical trial.  
Merck

	<b>O'Leary (Site PI)</b>	2014-2017
--	--------------------------	-----------

A registry for subjects with cirrhosis who achieve sustained virologic response following treatment with a Sofosbuvir-based regimen without interferon for chronic hepatitis C infection in Gilead-sponsored trials.  
Gilead

	<b>O'Leary (Site PI)</b>	2014-2017
--	--------------------------	-----------

A phase 2, randomized, double-blind, placebo-controlled, dose-finding, clinical trial evaluating the efficacy and safety of Obeticholic Acid in subjects with primary sclerosing cholangitis.  
Intercept

	<b>O'Leary (Site PI)</b>	2014-2017
--	--------------------------	-----------

A phase 3b, double-blind, randomized, placebo-controlled, multi-center study evaluating the effect of Obeticholic Acid on clinical outcomes in subjects with primary biliary cirrhosis.  
Intercept

E-mail: dr\_jackieo@yahoo.com

Phone: 469-271-7829

**O'Leary (Site PI)**

2014-2017

A phase 2, multicenter, open-label study to investigate the safety and efficacy of Ledipasvir/Sofosbuvir fixed dose combination administered in patient infected with chronic HCV for use in the peri-operative liver transplantation setting.  
Gilead

**O'Leary (Site PI)**

12/13-2017

HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study  
University of Florida

NCT01938430

**O'Leary (Site PI)**

9/2013-2017

A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected with Chronic HCV who have Advanced Liver Disease or are Post-Liver Transplant  
Gilead Sciences Multicenter Trial

NCT01804829

**O'Leary (Site PI)**

8/2013-2017

A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients. This substudy will evaluate the effect of Civacir on preformed and *de novo* donor specific antibodies.  
Biotest Multicenter Trial

NCT01779518

**O'Leary (Site PI)**

2/13-9/14

An Expanded Access Phase 2 Study of Sofosbuvir with Ribavirin and with or without Pegylated Interferon for 24 weeks in Subjects who have undergone Liver Transplantation and Who Have Aggressive, Recurrent Hepatitis C infection  
Gilead Sciences Multicenter Trial

NCT01323244

**O'Leary (Site PI)**

1/13-2017

A Phase III open label trial of TMC435 in combination with peginterferon alfa-2a and ribavirin for HCV genotype-1 infected subjects who participated in the placebo group of a Phase II/III TMC435 study (C201, C205, C206, C208, C216 or HPC3007), or who received short-term (up to 14 days) direct-acting antiviral treatment for hepatitis C infection in a selected Tibotec sponsored Phase I study.  
Tibotec

**O'Leary (Site PI)**

1/13-2017

A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment-resistant mutations or the durability of sustained virological response (SVR) in patients treated with DAA-containing regimens for chronic hepatitis C infection (CHC)  
F. Hoffmann-La Roche Inc Multicenter Trial

**O'Leary (Site PI)**

A phase 2 open-label study in patients with recurrent genotype 1 hepatitis C post-orthotopic liver transplant to explore the safety and efficacy of simeprevir and sofosbuvir with and without ribavirin.  
Jansen

E-mail: dr\_jackieo@yahoo.com

Phone: 469-271-7829

**O'Leary (Sub-I)**

The ATOMIC Study: A multicenter, open-label, randomized, duration-finding study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics following oral administration of PSI-7977 in combination with pegylated interferon and Ribavirin.

Gilead

**O'Leary (Site-PI)**

An open-label study of GS-7977 + Ribavirin for 12 weeks in subjects with chronic HCV infection who participated in prior studies evaluating GS-7977.

Gilead

**O'Leary (Sub-I)**

A phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including Peginterferon Alfa-2a and Ribavirin in treatment-naïve patients.

Jansen

**O'Leary (Co-PI)**

Long-term follow-up of subjects in phase 1, 2 or 3 clinical trial in which Boceprevir or Narlaprevir was administered for the treatment of Hepatitis C.

Merck

**O'Leary (Site PI)**

An observational prospective registry to identify demographics and clinical characteristics of patients hospitalized with euvolemic and hypovolemic hyponatremia and assess the comparative effectiveness of available treatments and the impact on resource utilization.

Ocera Therapeutics, Inc.

**O'Leary (Site PI)**

An open-label study to explore the clinical efficacy of GS-7977 with Ribavirin administered pre-transplant in preventing hepatitis C virus recurrence post-transplant.

Gilead

**O'Leary (Site PI)**

A multi-center 3-year follow-up study to assess the viral activity in patients who failed to achieve sustained virologic response in Novartis-sponsored Alisporivir studies for chronic Hepatitis C patients.

Novartis

**O'Leary (Site PI)**

A 2-part, open-label study of Telaprevir in combination with Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in subjects chronically infected with genotype 1 hepatitis C virus following liver transplantation.

Vertex

**O'Leary (Site PI)**

8/12-2017

A multi-center long term follow-up study to assess the durability of sustained virologic response in alisporivir-treated chronic Hepatitis C patients

Novartis Pharmaceuticals Multicenter Trial

E-mail: dr\_jackieo@yahoo.com

Phone: 469-271-7829

**O'Leary (Site PI)**

7/12-2/14

A Randomized, Open-Label, Multicenter Study of the Safety, Efficacy, and Tolerability of Combination Treatment of Setrobuvir, Danoprevir, Ritonavir, and Copegus® with or without Mericitabine in HCV Genotype 1–Infected Patients Who are Either Treatment Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment  
F. Hoffmann-La Roche IncMulticenter Trial

NCT01559844

**O'Leary (Site PI)**

3/2012-2017

Study P7977-2025: An Open-Label Study to Explore the Clinical Efficacy of GS-7977 with Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant.

Gilead Sciences Multicenter Trial

NCT01467505

**O'Leary (Site PI)**

2/12-5/14

REFRESH-VX-950-117: An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients  
Vertex Pharmaceuticals, Inc sponsored Multicenter Trial

NCT01466790

**O'Leary (Site PI)**

11/11-7/14

An exploratory Phase IIa, randomized, open-label trial to investigate the efficacy and safety of 12 weeks or 24 weeks of TMC435 in combination with PSI-7977 with or without ribavirin in chronic hepatitis C genotype 1-infected prior null responders to peginterferon/ribavirin therapy.

**O'Leary (Site PI)**

10/11-4/14

A Phase II, Randomized, Double-Blind, Multicenter, Parallel Group Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug RO5024048 in Combination with Telaprevir and Pegasys®/Copegus® in Subjects with Chronic Hepatitis C Genotype 1 Virus Infection Who Were Prior Null Responders to Treatment with Pegylated Interferon/Ribavirin

F. Hoffmann-La Roche IncMulticenter Trial

**O'Leary (Site PI)**

3/11-3/14

A randomized, double-blind, placebo-controlled trial of the efficacy and safety of DEB025/Alisporivir in combination with standard of care in hepatitis C genotype 1 treatment-naïve patients

Novartis Pharmaceuticals Multicenter Trial

**O'Leary (Site PI)**

3/11-6/14

A phase III, randomized, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 24 weeks and BI 201335 240 mg for 12 weeks in combination with pegylated interferon-a and ribavirin in treatment-naïve patients with genotype 1 chronic hepatitis C infection

Boehringer Ingelheim PharmaceuticalsMulticenter Trial

**O'Leary (Site PI)**

1/11-2017

E-mail: dr\_jackieo@yahoo.com

Phone: 469-271-7829

A Long-Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection (SVR Registry)

Gilead Sciences Multicenter Trial

**O'Leary** (Site PI)

1/11-2017

A Long-Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection

Gilead Sciences Multicenter Trial

**O'Leary** (Site PI)

1/07-6/2014

Long-Term Follow-up of Subjects in Phase 1, 2 or 3 Clinical Trial in which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis C

Schering Plough/MerckMulticenter Trial

NCT01143246

**O'Leary** (Site PI)

9/10-7/13

REVERSE: A Placebo-Controlled, Double-Blind Study to confirm the reversal of Hepatorenal Syndrome Type 1 with Terlipressin

Ikaria Holdings Inc. sponsored Multicenter Trial

NCT01240668

**O'Leary** (Site PI)

11/10-7/13

Hyponatremia Registry for Patients with euvolemic and hypervolemic hyponatremia (HN Registry)

Otsuka America Pharmaceutical sponsored Multicenter Trial